Evidence mapPaperPMID 34082067Full record

ArticleBioorganic & medicinal chemistry letters2021

Development and evaluation of [

Harsimran Kaur, Megan R Felix, Christopher Liang, Jogeshwar Mukherjee

Open access · greenAbstract read
In one paragraph

Article in Bioorganic & medicinal chemistry letters, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 15 citations in OpenAlex.

  1. [Synapse (New York, N.Y.) · 2025
    Article
  2. Reduction in [Brain research · 2025
    Article
  3. Review
  4. [International journal of molecular sciences · 2024
    Article
  5. [Neurology international · 2024
    Article
  6. Article
  7. [Molecules (Basel, Switzerland) · 2023
    Article
  8. Article
  9. Abnormal [Synapse (New York, N.Y.) · 2023
    Article
  10. Article
  11. Development of [Molecules (Basel, Switzerland) · 2023
    Article
  12. Article
  13. [Molecules (Basel, Switzerland) · 2022
    Article
  14. NRM 2021 Abstract Booklet.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Harsimran KaurPreclinical Imaging, Department of Radiological Sciences, University of California, Irvine 92697, USA.
Megan R FelixPreclinical Imaging, Department of Radiological Sciences, University of California, Irvine 92697, USA.
Christopher LiangPreclinical Imaging, Department of Radiological Sciences, University of California, Irvine 92697, USA.
Jogeshwar MukherjeePreclinical Imaging, Department of Radiological Sciences, University of California, Irvine 92697, USA. Electronic address: j.mukherjee@uci.edu.
University of California, Irvine · US

Funding

CORE--NEUROPATHOLOGYP30AG019610 · SUN HEALTH RESEARCH INSTITUTE · 2001 to 2005
$4.7M
NIA NIH HHS P30 AG019610NIA NIH HHS R01 AG029479NIA NIH HHS RF1 AG029479NINDS NIH HHS U24 NS072026
6 · The paper itself

Abstract

Positron emission tomographic (PET) studies of amyloid β (Aβ) accumulation in Alzheimer's disease (AD) have shown clinical utility. The aim of this study was to develop and evaluate the effectiveness of a new fluorine-18 radiotracer [

Indexed as

Drug DevelopmentAlzheimer DiseaseBrainHumansMolecular StructurePlaque, AmyloidPositron-Emission Tomography[(18)F]FlotazaAlzheimer’s diseaseHuman Aβ plaquesPET imaging

Identifiers

PMID34082067
PMCPMC8379902
OpenAlexW3164660898

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.